• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

Introduction to 4-cyclopropyl-6-ethylpyrimidin-2-amine (CAS No. 1341144-24-8)

4-cyclopropyl-6-ethylpyrimidin-2-amine, identified by its Chemical Abstracts Service (CAS) number 1341144-24-8, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrimidine class, a structurally versatile scaffold that is widely explored for its biological activity and potential therapeutic applications. The presence of both cyclopropyl and ethyl substituents in its molecular structure contributes to its unique chemical properties and reactivity, making it a valuable intermediate in the synthesis of more complex pharmacological agents.

The 4-cyclopropyl-6-ethylpyrimidin-2-amine molecule exhibits a pyrimidine core, which is a six-membered aromatic ring containing two nitrogen atoms. This core structure is fundamental to many biologically active compounds, including nucleoside analogs and antiviral agents. The cyclopropyl group at the 4-position and the ethyl group at the 6-position introduce steric and electronic effects that can influence the compound's interactions with biological targets. Such modifications are strategically employed in drug design to optimize binding affinity, metabolic stability, and pharmacokinetic profiles.

In recent years, there has been a surge in research focused on developing novel pyrimidine derivatives with enhanced therapeutic efficacy. The 4-cyclopropyl-6-ethylpyrimidin-2-amine structure has been investigated for its potential as a precursor in the synthesis of inhibitors targeting various enzymatic pathways relevant to cancer, inflammation, and infectious diseases. For instance, studies have explored its utility in generating kinase inhibitors, where the pyrimidine ring serves as a hinge-binding motif, while the substituents fine-tune interactions with the active site of the target protein.

One of the most compelling aspects of 4-cyclopropyl-6-ethylpyrimidin-2-amine is its role in developing next-generation antiviral agents. The pyrimidine scaffold is closely related to natural nucleobases found in DNA and RNA, making it an ideal candidate for designing molecules that can interfere with viral replication. Recent advancements in computational chemistry have enabled researchers to predict how modifications like those present in 4-cyclopropyl-6-ethylpyrimidin-2-amine can enhance binding to viral polymerases or integrases, thereby inhibiting pathogenic processes.

The synthesis of 4-cyclopropyl-6-ethylpyrimidin-2-amine typically involves multi-step organic reactions that require precise control over reaction conditions. Key synthetic strategies often include cyclization reactions to form the pyrimidine ring, followed by functional group transformations to introduce the cyclopropyl and ethyl moieties. Advances in catalytic methods have allowed for more efficient and sustainable synthetic routes, reducing waste and improving yields. These developments are crucial for scaling up production while adhering to green chemistry principles.

The pharmacological evaluation of 4-cyclopropyl-6-ethylpyrimidin-2-amine has revealed promising results in preclinical studies. Its derivatives have shown inhibitory activity against several enzymes implicated in disease pathways, including Janus kinases (JAKs) and tyrosine kinases. Such kinases are often dysregulated in cancer and autoimmune disorders, making them attractive targets for therapeutic intervention. The structural features of 4-cyclopropyl-6-ethylpyrimidin-2-amines, particularly the nitrogen-rich pyrimidine core and substituent-induced conformational flexibility, contribute to its potent binding interactions with these enzymes.

In addition to its applications in oncology, 4-cyclopropyl-6-ethylpyrimidin-2-amines have been explored for their potential in treating inflammatory diseases. By modulating inflammatory signaling pathways, such compounds may offer relief for conditions like rheumatoid arthritis or inflammatory bowel disease. Preclinical models have demonstrated that certain derivatives can reduce pro-inflammatory cytokine production while maintaining immunological balance, suggesting a favorable therapeutic profile.

The development of 4-cyclopropyl-6-ethylpyrimidin-based drugs also benefits from advances in drug delivery systems. Nanotechnology-based formulations have been investigated to enhance bioavailability and target specificity. For example, liposomes or polymeric nanoparticles can encapsulate these compounds, allowing for controlled release at disease sites and minimizing systemic side effects. Such innovations are essential for translating promising preclinical findings into effective clinical treatments.

Regulatory considerations play a critical role in advancing 4-cyclopropylhexylethylenopyrimidine derivatives into clinical use. Compliance with Good Manufacturing Practices (GMP) ensures that synthesized compounds meet stringent quality standards before being tested in humans. Additionally, rigorous toxicological assessments are conducted to evaluate safety profiles across various exposure levels. These steps are integral to navigating regulatory hurdles and ensuring patient safety during drug development.

The future direction of research on 4-cyclopropylhexylethynypyridines lies in expanding their chemical diversity through structural analogs and exploring new therapeutic indications. Collaborative efforts between academia and industry are fostering innovation by integrating high-throughput screening technologies with machine learning algorithms to accelerate hit identification and lead optimization processes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)